Literature DB >> 22189819

The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.

Peng Hou1, Dingxie Liu, Jianli Dong, Mingzhao Xing.   

Abstract

Although BRAF(V600E) is well known to play an important role in the tumorigenesis of melanoma, its molecular mechanism, particularly the epigenetic aspect, has been incompletely understood. Here, we investigated the role of BRAF(V600E) signaling in altering gene methylation in the genome of melanoma cells using a methylated CpG island amplification/CpG island microarray system and searched for genes coupled to the BRAF(V600E) signaling through methylation aberrations. The results indicated that a wide range of genes with broad functions were linked to BRAF(V600E) signaling through their hyper- or hypomethylation. Expression of 59 genes hypermethylated upon BRAF knockdown was selectively tested and found to be largely correspondingly underexpressed, suggesting that these genes were naturally hypomethylated, and overexpressed with BRAF(V600E) in melanoma. This BRAF(V600E)-promoted hypomethylation was confirmed on genes selectively examined in primary melanoma tumors. Some of these genes were functionally tested and demonstrated to play a role in melanoma cell proliferation and invasion. As a mechanism of aberrant gene methylation driven by BRAF(V600E), expression of the DNA methyltransferase 1 and histone methyltransferase EZH2 was profoundly affected by BRAF(V600E). We have thus uncovered a previously unrecognized prominent epigenetic mechanism in the tumorigenesis of melanoma driven by BRAF(V600E). Many of the functionally important genes controlled by the BRAF(V600E) signaling through aberrant methylation may prove to be novel therapeutic targets for melanoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22189819      PMCID: PMC3293379          DOI: 10.4161/cc.11.2.18707

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  40 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells.

Authors:  Huidong Shi; Pearlly S Yan; Chuan-Mu Chen; Farahnaz Rahmatpanah; Catherine Lofton-Day; Charles W Caldwell; Tim Hui-Ming Huang
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

3.  Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.

Authors:  Peng Hou; Dingxie Liu; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2011-11-14       Impact factor: 5.678

4.  CDC42 and FGD1 cause distinct signaling and transforming activities.

Authors:  I P Whitehead; K Abe; J L Gorski; C J Der
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

5.  Regulation of DNA methylation by the Ras signaling pathway.

Authors:  A R MacLeod; J Rouleau; M Szyf
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

6.  Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays.

Authors:  P S Yan; C M Chen; H Shi; F Rahmatpanah; S H Wei; C W Caldwell; T H Huang
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

7.  Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients.

Authors:  C Deng; M J Kaplan; J Yang; D Ray; Z Zhang; W J McCune; S M Hanash; B C Richardson
Journal:  Arthritis Rheum       Date:  2001-02

8.  Transcriptional regulation of the human DNA Methyltransferase (dnmt1) gene.

Authors:  P Bigey; S Ramchandani; J Theberge; F D Araujo; M Szyf
Journal:  Gene       Date:  2000-01-25       Impact factor: 3.688

9.  BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.

Authors:  T Kambara; L A Simms; V L J Whitehall; K J Spring; C V A Wynter; M D Walsh; M A Barker; S Arnold; A McGivern; N Matsubara; N Tanaka; T Higuchi; J Young; J R Jass; B A Leggett
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  49 in total

1.  Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.

Authors:  Chi Luo; Jinghao Sheng; Miaofen G Hu; Frank G Haluska; Rutao Cui; Zhengping Xu; Philip N Tsichlis; Guo-Fu Hu; Philip W Hinds
Journal:  Cancer Res       Date:  2013-05-06       Impact factor: 12.701

2.  Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Authors:  Yuliya V Katlinskaya; Kanstantsin V Katlinski; Qiujing Yu; Angelica Ortiz; Daniel P Beiting; Angela Brice; Diwakar Davar; Cindy Sanders; John M Kirkwood; Hallgeir Rui; Xiaowei Xu; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

Review 3.  Diverse involvement of EZH2 in cancer epigenetics.

Authors:  Pamela Völkel; Barbara Dupret; Xuefen Le Bourhis; Pierre-Olivier Angrand
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

4.  H3K27me3-mediated PGC1α gene silencing promotes melanoma invasion through WNT5A and YAP.

Authors:  Chi Luo; Eduardo Balsa; Elizabeth A Perry; Jiaxin Liang; Clint D Tavares; Francisca Vazquez; Hans R Widlund; Pere Puigserver
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 5.  Epigenetic markers in melanoma.

Authors:  Weimin Guo; Ting Xu; Jonathan J Lee; George F Murphy; Christine G Lian
Journal:  Melanoma Manag       Date:  2015-11-24

Review 6.  Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Laura F Hutchins; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

Review 7.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

8.  JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic.

Authors:  Bailing Chen; Jia Liu; Qingshan Chang; Kevin Beezhold; Yongju Lu; Fei Chen
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

9.  Phase II trial of vorinostat in advanced melanoma.

Authors:  N B Haas; I Quirt; S Hotte; E McWhirter; R Polintan; S Litwin; P D Adams; T McBryan; L Wang; L P Martin; M vonMehren; R K Alpaugh; J Zweibel; A Oza
Journal:  Invest New Drugs       Date:  2014-01-25       Impact factor: 3.850

10.  Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas.

Authors:  Sriram Venneti; Michelle Madden Felicella; Thomas Coyne; Joanna J Phillips; Daniel Gorovets; Jason T Huse; Julia Kofler; Chao Lu; Tarik Tihan; Lisa M Sullivan; Mariarita Santi; Alexander R Judkins; Arie Perry; Craig B Thompson
Journal:  J Neuropathol Exp Neurol       Date:  2013-04       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.